Prescription drug · ANDA
Meropenem NDC 81962-002
Meropenem anhydrous 2 g/1 · Injection · Intravenous · BROOKS STERISCIENCE LIMITED
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 81962-002-08 | 81962000208 | 6 INJECTION in 1 CARTON (81962-002-08)Marketed from Jun 27, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Meropenem
- Generic name (nonproprietary)
- meropenem
- Active ingredients
- Meropenem anhydrous — 2 g/1
- Dosage form
- Injection
- Route
- Intravenous
- Labeler
- BROOKS STERISCIENCE LIMITEDNDC labeler code 81962
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 219084
- Marketing start
- Listing expires
- Other FDA classes
- Carbapenems (Chemical structure)
- Identifiers
- Product ID 81962-002_3877deca-080e-eeca-e063-6394a90a691aSPL ID 3877deca-080e-eeca-e063-6394a90a691aSPL set ID 6902fee1-6022-4145-a79a-4680ad1fb1e8RxCUI 2664894UNII YOP6PX0BAO
- Pharmacologic class
- Penem Antibacterial
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N481962000208followed by a unit qualifier and the quantityPackage 81962-0002-08. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
1.1 Bacterial Meningitis (Pediatric Patients 3 Months of Age and Older Only) Meropenem for Injection is indicated for the treatment of bacterial meningitis caused by Haemophilus influenzae, Neisseria meningitidis and penicillin-susceptible isolates of Streptococcus pneumoniae , in pediatric patients 3 months of age and older. Meropenem for injection has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis. 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for Injection and other antibacterial drugs, Meropenem for Injection should only be used to treat or prevent infections that are pr…
Excerpt only. Read the full label for complete information.
About NDC 81962-002
- What is NDC 81962-002?
- 81962-002 is the product NDC for Meropenem, Meropenem anhydrous 2 g/1 injection, listed with the FDA by BROOKS STERISCIENCE LIMITED. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Meropenem.
- What is the active ingredient?
- Meropenem anhydrous.
- Who is the labeler?
- BROOKS STERISCIENCE LIMITED, NDC labeler code 81962. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Meropenem?
- 42 other product NDCs are listed under this name. See all Meropenem NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Meropenem products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Meropenem | Meropenem 500 mg/10mL | Injection, Powder, For solutionIntravenous | Hikma Pharmaceuticals USA Inc. | 0143-9485 | 00143-9485-10 |
| Meropenem | Meropenem 1 g/20mL | Injection, Powder, For solutionIntravenous | Hikma Pharmaceuticals USA Inc. | 0143-9486 | 00143-9486-10 |
| Meropenem | Meropenem 500 mg/20mL | Injection, Powder, For solutionIntravenous | Sagent Pharmaceuticals | 25021-160 | 25021-0160-20 |
| Meropenem | Meropenem 1 g/30mL | Injection, Powder, For solutionIntravenous | Sagent Pharmaceuticals | 25021-161 | 25021-0161-30 |
| Meropenem | Meropenem 1 g/20mL | InjectionIntravenous | Civica, Inc. | 72572-410 | 72572-0410-10 |
| Meropenem | Meropenem 500 mg/20mL | InjectionIntravenous | Civica, Inc. | 72572-412 | 72572-0412-10 |
| Meropenem | Meropenem anhydrous 2 g/1 | InjectionIntravenous | Mylan Institutional LLC | 72078-081 | 72078-0081-06 |
| Meropenem | Meropenem 500 mg/20mL | InjectionIntravenous | Qilu Antibiotics Pharmaceutical Co., Ltd. | 51810-502 | 51810-0502-02 |
| Meropenem | Meropenem 1 g/30mL | InjectionIntravenous | Qilu Antibiotics Pharmaceutical Co., Ltd. | 51810-503 | 51810-0503-02 |
| Meropenem | Meropenem 500 mg/20mL | InjectionIntravenous | Hikma Pharmaceuticals USA Inc. | 0143-9430 | 00143-9430-10 |
Other NDCs under ANDA 219084
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Meropenem | Meropenem anhydrous 2 g/1 | InjectionIntravenous | Mylan Institutional LLC | 72078-081 |